ABEO · Abeona Therapeutics Inc.

Track ABEO — free

$5.25 +0.09 (+1.74%) At close · Sep 30

Russell 2000 member Rebalance outlook locked

Market Cap

$299.07M

57.18M

Volume · Sep 30 1.13M Avg daily vol (3M) 1.44M

Up next

Next earnings call

Nov 30, 2026 Est · unconfirmed · in 9 wks

Latest filing: 10-Q

filed Aug 13, 2026

Q1 2026 earnings call transcript

call held May 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$25.52M

Trailing 12 months

Net income (TTM)

−$62.89M

Trailing 12 months

Revenue growth YoY

+2,745.0%

Year over year

Operating margin

-1,536.9%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-27.3%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$131.84M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-14.4%

Year over year · fewer shares

Price change (1Y)

-3.2%

Trailing year

Short interest

27.5%

Latest settlement · 12.0 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −5%

below

Price vs 50-day avg −13%

below

RSI (14) 37

neutral

MACD trend Negative

52-week position 33%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −12%

trailing

6-month return +3%

trailing

YTD return 0%

this year

Relative strength −10%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $6 › 200d $6 — 50d above 200d

Institutional flow Accumulating

+17% holders QoQ · +31 funds added

Insider flow Distributing

Net -$1.1M over 90 days · 100% sells

Short interest Rising

27.53% of float · ▲ +3.9% MoM · 12.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

127 holders — near 3-yr high, broad support

Squeeze score 70

high risk · 0–100

Fundamentals

Strong

Revenue growth +258%

Y/Y

EPS growth +165%

Y/Y

Free cash flow $-84.3M

Balance sheet $58.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 53%

annualized · 1-yr

Max drawdown −31%

past year

ATR 4.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−5% Bearish

Price vs 50-day avg

−13% Bearish

RSI (14)

37 Neutral

MACD trend

Negative Bearish

52-week position

33% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $6 › 200d $6 — 50d above 200d

Institutional flow Accumulating

+17% holders QoQ · +31 funds added

Insider flow Distributing

Net -$1.1M over 90 days · 100% sells

Short interest Rising

27.53% of float · ▲ +3.9% MoM · 12.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

127 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $4 Now $5 · 33% Range high $7

vs 200-day avg -5% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
patient treatments completed since launch	12	since launch through Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ABEO Abeona Therapeutics Inc. this stock	$299.07M	-0.4%	+258.2%	—	27.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+15.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-1.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+553.0%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

127

% held: 71.9%
Net QoQ: -579.4K sh
Top holder: Nantahala Capital Managem…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

15.7M

Days to cover: 12.0d
Change: +587.9K sh

View

Short Volume

Short vol %

56%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

18.5K

Value: $111.3K
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

48.6%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$1.1M

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Financials

Revenue (FY)

$5.8M

Net income (FY): $71.2M
EPS diluted: $1.01

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 16, 2026
This year: 17

View

Proposed Sales

Value

$47.4K

Shares: 9.2K
Filed: Sep 29, 2026

View

Earnings & Events

Earnings Calls

Last call

Sep 16, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ABEO	-5.1%	-12.2%	+2.5%	-10.3%	-0.4%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	-4.4%	-12.3%	-9.6%	-9.7%	-12.2%

Key facts CIK 318306 CUSIP 00289Y206 13F (30d) 4 filings 4 filers Visit website Investor relations

ABEO · Abeona Therapeutics Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance